Publicaciones en colaboración con investigadores/as de Universidad del País Vasco/Euskal Herriko Unibertsitatea (20)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

  2. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 10, pp. 1248-1259

2023

  1. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  2. Splanchnic Vein Thrombosis in Inflammatory Bowel Disease: An Observational Study from the ENEIDA Registry and Systematic Review

    Journal of Clinical Medicine, Vol. 12, Núm. 23

2022

  1. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

2019

  1. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

2005

  1. Time-dependent pharmacokinetics of cyclosporine (Neoral®) in de novo renal transplant patients

    Journal of Clinical Pharmacy and Therapeutics, Vol. 30, Núm. 6, pp. 549-557

2004

  1. Influence of formulation on propofol pharmacokinetics and pharmacodynamics in anesthetized patients

    Acta Anaesthesiologica Scandinavica, Vol. 48, Núm. 8, pp. 1038-1048

  2. Techniques: New approaches to the delivery of biopharmaceuticals

    Trends in Pharmacological Sciences, Vol. 25, Núm. 7, pp. 382-387

2003

  1. Drug delivery in biotechnology: Present and future

    Current Opinion in Biotechnology, Vol. 14, Núm. 6, pp. 659-664

1997

  1. Influence of route of administration and dosage form in the pharmacokinetic and bioavailability of salbutamol

    European Journal of Drug Metabolism and Pharmacokinetics, Vol. 22, Núm. 2, pp. 145-150

1996

  1. Correlation of 'in vitro' release and 'in vivo' absorption characteristics of four salbutamol sulphate formulations

    International Journal of Pharmaceutics, Vol. 139, Núm. 1-2, pp. 45-52

1994

  1. On the employment of λ-carrageenan in a matrix system. II. λ-Carrageenan and hydroxypropylmethylcellulose mixtures

    Journal of Controlled Release, Vol. 30, Núm. 2, pp. 175-182

1993

  1. On the employment of λ-carrageenan in a matrix system. I. Sensitivity to dissolution medium and comparison with Na carboxymethylcellulose and xanthan gum

    Journal of Controlled Release, Vol. 26, Núm. 2, pp. 119-127

1992

  1. Cinética de disposición del salbutamol tras su administración por vías endovenosa yoral en forma convencional y como una nueva formulación de liberación sostenida

    Reunión Científica de la Asociación de Docentes de Farmacia Galénica (1º. Madrid. 1992)

  2. Efecto de dosis equimoleculares de cimetidina y ranitidina sobre la eliminación deteofilina

    Reunión Científica de la Asociación de Docentes de Farmacia Galénica (1º. Madrid. 1992)

1987

  1. Contribución del Servicio de Farmacia en un programa de tratamiento deheroinómanos.

    Congreso Nacional de la Asociación Nacional de Farmacéuticos de Hospitales. (32. Salamanca. 1987)

  2. Estudio de bioequivalencia de dos formulaciones orales de paracetamol

    Farmacia Hospitalaria XXXII. Tomo I (Madrid : Asociación Española de Farmacéuticos de Hospitales, 1987), pp. 117-123

  3. Monitoring of serum levels of amitriptyline in overdose.

    Proceedings del III Congreso Europeo de Biofarmacia y Farmacocinética

1984

  1. Farmacocinética de amoxapina y sus metabolitos activos en voluntarios sanos tras laadministración de una dosis de 100 mg

    Proceedings del II Congreso Europeo de Biofarmacia y Farmacocinética. Vol III